HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Young, R. L. Articles by Dorfman, S. G. Search for Related Content PubMed PubMed Citation Articles by Young, R. L. Articles by Dorfman, S. G.

Pure Follicular Thyroid Carcinoma: Impact of Therapy in 214 Patients

Wilford Hall USAF Medical Center, Lackland AFB, Texas
Brooks AFB, Texas
University of Nevada, Reno, Nevada

Correspondence: For reprints contact: Colonel Robert L. Young, USAF, MC, Chairman, Dept. of Endocrinology and Metabolism (SGHME), Wilford Hall USAF Medical Ctr., Lackland AFB, TX 78236.

ABSTRACT

Records of 214 patients with pure follicular thyroid carcinoma were reviewed in detail to evaluate the circumstances of initial presentation and therapy on ultimate outcome. Mean follow up was 8.8 yr. The only deaths directly attributable to the thyroid carcinoma occurred in patients with distant metastases at the time of presentation. There were 20 recurrences in the 182 patients considered free of disease after initial therapy. Overall recurrence rate was not affected by the presence of positive cervical nodes or extent of thyroid surgery. Postoperative recurrence rate was decreased by both radioiodine and thyroid-hormone therapy. Extensive histologic invasion of the capsule of the nodule and thyroid appeared to be associated with an increase in recurrence rate. Postoperative thyroid-hormone is required therapy in all patients with pure follicular thyroid carcinoma. Radioiodine therapy is indicated in patients with extensive invasion and we favor its use in all patients.

This article has been cited by other articles:

				A. M. Sawka, K. Thephamongkhol, M. Brouwers, L. Thabane, G. Browman, and H. C. Gerstein A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3668 - 3676. [Abstract] [Full Text] [PDF]

				M. Schlumberger Use of Radioactive Iodine in Patients with Papillary and Follicular Thyroid Cancer: Towards A Selective Approach J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4201 - 4203. [Full Text]

				L. E. Sanders and B. Cady Differentiated Thyroid Cancer: Reexamination of Risk Groups and Outcome of Treatment Arch Surg, April 1, 1998; 133(4): 419 - 425. [Abstract] [Full Text] [PDF]